Spectrum News, December 1, 2016. Why would anyone vote against “cures,” especially “21st century cures?” Here’s why many health policy and consumer advocacy groups — including the National Center for Health Research — strongly oppose the bill and are asking senators not to pass the bill next week.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Cancer Drugs May Remain Approved Despite Lack of Benefit
Reuters, December 1, 2016. Researchers evaluated studies done on 18 cancer drugs approved between 2008 and 2012 by the FDA. None of the drugs had been found to prolong life, and only one had enough evidence to say it improved quality of life. Yet, all but one retained its approval status.
Read More »To Fund Projects Like the Cancer Moonshot, Congress Had to Strip Away Some of the FDA’s Most Important Regulatory Powers
Quartz, December 1, 2016. The 21st Century Cures Act passed in the House, but comes with a lot of regulatory compromise and threats to patient safety. Most notably, Senator Warren and Senator Sanders oppose the bill along with NCHR President Diana Zuckerman due to patient safety concerns and breaks for Big Pharma. “It really is a David and Goliath issue of where the money is,” said Dr. Zuckerman.
Read More »House Passes Most Lobbied Bill in Recent History, Heads to Senate
CBS News, November 30, 2016. Dr. Diana Zuckerman of the National Center For Health Research described the Cures Act as a “misnomer to start with.” She cited two issues with the bill: it lowers the standards for medical products, drugs and devices — and the money outlined in the bill is promised, not guaranteed.
Read More »Congress Poised To Pass Sweeping Law Covering FDA And NIH
NPR and WBUR, November 29, 2016. NCHR President, Diana Zuckerman, says she’s concerned that the 21st Century Cures act will make it even easier for drug companies to use the express lane for approval.
Read More »